Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	25.18B
Revenue (ttm)	11.58B
Net Income (ttm)	570.05M
Shares Out	231.00M
EPS (ttm)	2.47
PE Ratio	44.17
Forward PE	n/a
Dividend	2.10 (1.89%)
Ex-Dividend Date	Nov 17, 2025

Volume	275,555
Average Volume	208,550
Open	115.00
Previous Close	114.70
Day's Range	112.50 - 115.20
52-Week Range	92.40 - 147.50
Beta	-0.55
RSI	48.59
Earnings Date	Oct 30, 2025

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories that include oncology, hematology, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointesti...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,162
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In 2024, Beacon Pharmaceuticals's revenue was 10.70 billion, an increase of 25.76% compared to the previous year's 8.51 billion. Earnings were 521.01 million, an increase of 2.19%.